(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
In spite of the development of various anticancer drugs, the therapy of cancer has remained challenging for decades. The current therapy of cancer is overwhelmed because of the inability to deliver therapeutics to all regions of a tumor in effective therapeutic concentrations, intrinsic or acquired resistance to the treatment with currently available agents via genetic and epigenetic mechanisms, and toxicity. As a result, cancer therapy using conventional therapeutics and different types of treatment regimens using this therapeutics has not led to a convincing survival benefit of the patients. In this context, Macromolecular therapeutics offer several advantages over conventional low molecular therapeutics by various ways such as, enable the use of larger doses of these agents by limiting the toxicity, by enhanced permeability and retention into tumors, by tumor targeting using tumor-specific antibodies, by specific inhibition of oncogenes using anticancer oligonucleotides etc. Cancer treatment using this macromolecular therapeutics has considerably improved the survival benefit for patients. As a result, various macromolecular therapeutics are already commercialized or are under clinical development. Although we are far from a real magic bullet today, looking at the pace of research and current success in this field of macromolecular therapeutics, it appears that we are approaching a magic bullet for the efficient treatment of cancer. Thus, we believe that the subject of this book is very timely, and that the book will fill an unmet need in the market.
This book is unique and assembles various types and aspects of macromolecular anticancer therapeutics for cancer therapy in one shell and conveys the importance of this interdisciplinary field to the broad audience. Thus, in a nutshell, this book details the basics of cancer, and various therapeutic strategies such as those based on macromolecular therapeutics hence can become an important reference for practitioners, oncologists, medical pharmacologists, medicinal chemists, biomedical scientists, experimental pharmacologists, pharmaceutical technologists, and particularly it can essentially become a handbook of macromolecular therapeutics for cancer therapy for graduates, post-graduates and Ph.D. students in these fields.
Contents:
I. Synthetic polymer-based anticancer prodrugs
Jindrich Kopecek (Departments of Pharmaceutics and Pharmaceutical Chemistry and of Bioengineering, University of Utah, Salt Lake City, Utah 84112)
HPMA-anticancer drug conjugates
Richard B. Greenwald (Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey 00854)
Poly(ethylene glycol)-anticancer drug conjugates
Chun Li (Department of Experimental Diagnostic Imaging, Box 59, The University of Texas, M.D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, TX 77030, USA)
Poly(L-glutamic acid)-anticancer drug conjugates
II. Natural polymer-based anticancer prodrugs
Felix Kratz (Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Strasse 117, D-79106 Freiburg, Federal Republic of Germany)
Protein-based anticancer conjugates
Andrew V. Schally (Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana)
Peptide and peptide hormone anticancer therapeutics
Yoshiharu Machida (Department of Drug Delivery Research, Hoshi University; 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan)
Chitosan and other polysaccharide anticancer conjugates
III. Antibody-directed cancer therapy
John R. Desjarlais
Xencor, Inc. CA 91016, United States
Engineering of antitumor antibodies
Victor S. Goldmacher (ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA)
Antibody-anticancer drug conjugates
David M. Goldenberg (Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.)
Immunoconjugate and radioimmunoconjugate anticancer therapeutics
Kenneth D. Bagshawe (Imperial College London, Department of Medical Oncology, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.)
Antibody-directed enzyme prodrug anticancer therapeutics
Paul M. Harari (University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA.)
EGFR-directed monoclonal antibodies
Gabriel N. Hortobagyi (Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX. usa)
Her2/neu-directed antibodies
John M. Kirkwood (Division of Hematology-Oncology, Department of Medicine, Hillman Cancer Center, Pittsburgh, PA 15232)
CTLA-4-directed monoclonal antibodies
Dario Neri (Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland)
Antibodies directed to tumor vasculature
IV. Lipid-based anticancer prodrugs
L. Harivardhan Reddy, Patrick Couvreur (Physicochimie, Pharmacotechnie et Biopharmacie, Faculty of Pharmacy, Universite Paris-Sud XI, Chatenay-Malabry, France)
Lipid-based prodrugs of anti-metabolite anticancer agents
Mitsuru Hashida (Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan)
Lipid-based prodrugs of non-anti-metabolite anticancer agents
V. Macromolecular nucleic acid therapeutics
Ernst Wagner (Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universitaet, Butenandtstr. 5-13, D-81377, Muenchen, Germany)
Macromolecular nucleic acid therapeutics
Uwe Zangemeister-Wittke (Department of Pharmacology, University of Bern, Bern, Switzerland.)
Antisense oligonucleotides
Brett P. Monia (Isis Pharmaceuticals, California 92008, USA)
Therapeutic MicroRNAs
Mark A. Behlke (Integrated DNA Technologies Inc., Coralville, IA 52241, USA)
Therapeutic siRNAs
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: March, 2012
Pages: 510
Weight: 973g
Availability: Available
Subcategories: Oncology, Pharmacology
Publisher recommends
L. Harivardhan Reddy
From the same series
Nicola Curtin
Jorge J. Castillo
Moulay A. Alaoui-Jamali
Gail Lewis Phillips
Frank E. Koehn
Beverly A. Teicher
Gary J. Kelloff
Ryan J. Sullivan
Gary K Schwartz
Val R Adams
Antonio Tito Fojo
William D. Figg
Steven Kanner
Giovanni Melillo
Masaki Terabe
Yves Pommier
Derek LeRoith
Beverly A. Teicher
Ann L. Jackman
Jorge J. Castillo
Manuel Hidalgo
Vinata B. Lokeshwar
Beverly A. Teicher
Moulay A. Alaoui-Jamali
Saïd M. Sebti
Frank E. Koehn
Rebecca G. Bagley
Vitaly A. Polunovsky
Benjamin Bonavida
Beverly A. Teicher
Alan M. Gewirtz
Michael A Morse
Janusz W. Rak
J. Silvio Gutkind
Maryann Foote
Zahid H. Siddik
Gavin J. Gordon
Masaki Terabe
Yves Pommier
Derek LeRoith
Neil J. Clendeninn
Howard L. Kaufman
John D. Haley
Manuel Hidalgo
Beverly A. Teicher
Ulrike Stein
Pat Price
Kelly K. Hunt
Mary L. Disis
David A. Gewirtz
Beverly A. Teicher
Sayed S. Daoud
Nicholas P. Farrell
Vinata B. Lokeshwar
Beverly A. Teicher
Giampietro Gasparini
Doriano Fabbro
Nicholas B. La Thangue
David E. Fisher
Beverly A. Teicher
John A. Hickman
Godefridus J. Peters
Julian Adams
Sonia Jakowlew
Antonio Giordano
Youcef M. Rustum
Michel Page
Gurmit Singh
Gary J. Kelloff
Moulay A. Alaoui-Jamali
Wafik S. El-Deiry
Keiko Hiyama
Amy M. Fulton
Federico Innocenti
Hak Choy
Sonia Jakowlew
Dennis M. Brown
Michael T. Lotze
Randall E. Harris
Eric Verdin
Benjamin Bonavida
Rebecca G. Bagley
Vitaly A. Polunovsky
Benjamin Bonavida
L. Harivardhan Reddy
V. Craig Jordan
Zahid H. Siddik
Erwin G. van Meir
Amy M. Fulton
Beverly A. Teicher
Keiko Hiyama
Gavin J. Gordon
David S. Ettinger
Federico Innocenti
John D. Haley
Benjamin Bonavida
Antonio Tito Fojo
Sonia Jakowlew
Sonia Jakowlew
Howard L. Kaufman
David A. Gewirtz
Beverly A. Teicher
Sayed S. Daoud
Pat Price
Michael T. Lotze
Ulrike Stein
Kelly K. Hunt
Godefridus J. Peters
Beverly A. Teicher
Eric Verdin